Manufacturers told to slash price of 3 cancer drugs

Tribune News Service

New Delhi, Updated At : 07:05 AM Oct 30, 2024 IST

Photo for representational purpose only.

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

The National Pharmaceutical Pricing Authority (NPPA) on Tuesday issued a memorandum directing drug manufacturers to reduce the MRP on three anti-cancer drugs — Trastuzumab, Osimertinib and Durvalumab.

This is in pursuance to the announcement made in the Budget for 25 exempting these three anti-cancer medicines from customs duty. The Finance Ministry had in July issued a notification reducing the customs duty to nil on these three anticancer drugs.

Further, the Department of Revenue, Ministry of Finance, issued notification on October 8 notifying the reduction in GST Rates from 12 per cent to 5 per cent.

Accordingly, there should be a reduction in the MRP of these drugs and the benefits of reduced duties should be passed on to consumers, the government said.

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles